The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to ...

Sanofi’s Pasteur vaccines unit and Translate Bio have expanded a collaboration to develop mRNA-based vaccines across all infectious disease areas. The deal builds on an agreement signed in 2018 ...

Sanofi SNY announced that the FDA has granted a fast-track designation to its mRNA vaccine candidate for the prevention of chlamydia infection. The company plans to begin a phase I/II study soon ...

The FDA has granted Fast Track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection.

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

(RTTNews) - Sanofi (SNYNF, SNY) announced Wednesday that the US Food and Drug Administration has granted fast track designation to the company's mRNA vaccine candidate for the prevention of ...

The surprise delay is casting new uncertainty on the fate of another vaccine awaiting FDA action: Moderna’s next-generation Covid-19 shot, called mRNA-1283, which is set for a decision by May 31.

Sanofi’s chlamydia vaccine candidate was designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis. The Food and Drug Administration (FDA ...